The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) against its key competitors in the Biotechnology industry. By analyzing ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

When examining Regeneron Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent: Regeneron Pharmaceuticals is in a ...

The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (SNY 0.12%) and Regeneron (REGN-3.69%). Could Pfizer beat Sanofi and Regeneron in the ...

Regeneron (REGN) closed the most recent trading day at $595.73, moving +1.54% from the previous trading session. This change lagged the S&P 500's 2.76% gain on the day. Meanwhile, the Dow gained 2 ...

Current Position of Regeneron Pharmaceuticals Currently trading with a volume of 389,940, the REGN's price is down by -1.07%, now at $1034.78. RSI readings suggest the stock is currently may be ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company, which became of interest to me after a close friend tipped me off about their potential to enter the weight loss market ...